Meeting
2015 ASCO Annual Meeting
The prognostic significance of CD45 expression by clonal bone marrow plasma cells in multiple myeloma.
Authors
Wilson I. Gonsalves
Mayo Clinic, Rochester, MN, Rochester, MN
Wilson I. Gonsalves , Vincent Rajkumar , William Morice , Michael Timm , Angela Dispenzieri , Francis Buadi , Martha Lacy , Yi Lin , David Dingli , Suzanne R. Hayman , Steven R. Zeldenrust , Stephen J. Russell , Nelson Leung , Prashant Kapoor , Morie A. Gertz , Shaji Kumar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 33, 2015 (suppl; abstr 8577)
DOI
10.1200/jco.2015.33.15_suppl.8577
Abstract #
8577
Poster Bd #
395
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Plasma cell proliferation by SynKii multiplex immunohistochemistry (mIHC) for clinical use in multiple myeloma (MM).
First Author: Scott Ely
Poster
2016 ASCO Annual Meeting
Dysregulation of nuclear factor-kappaB pathway in multiple myeloma patients at diagnosis and relapse.
First Author: Shivali Jasrotia
Poster
2013 ASCO Annual Meeting
Total therapy 5 (TT5) for newly diagnosed high-risk multiple myeloma (HRMM): Comparison with predecessor trials total therapy 3a and 3b (TT3 a/b).
First Author: Saad Zafar Usmani
Poster
2013 ASCO Annual Meeting
HM1.24/CD317-directed immunotoxin to eliminate malignant plasma cells in vitro and in vivo.
First Author: Martin Gramatzki